ping an-杏耀平台代理注册

on may 15, c&o and hailing pharm, a subsidiary of the listed company changjiang runfa group, signed a contract on the cooperation on lulite® luliconazole cream, and both parties reached a strategic cooperation on the product in the end retail market such as primary hospitals, pharmacies and clinics. through this cooperation, both sides will achieve resource sharing, mutual benefit and win-win, and give full play to their respective advantages to seek common development and develop new market.

lulite® luliconazole cream is a new generation of topical antifungal product originally developed in japan, which is a major breakthrough in the global antifungal field with three major features of fast-acting, non-recurring and short course of treatment, and only one dose per day.

hailing pharm owns the exclusive compound patent, and uses imported raw materials for its production. the drug is indicated for superficial fungal infections of the skin caused by sensitive bacteria: tinea pedis, tinea corporis, tinea cruris, and also for cutaneous candidiasis and lichen planus. it penetrates quickly, is powerfully fungicidal, and remains effective for 24 hours. its advantages including broad antibacterial spectrum, strong antibacterial activity, high rate of symptom improvement, less recurrence, shorter course of treatment, fewer side effects, less frequent medication, and higher compliance make it unanimously recognized by doctors and patients.

as a comprehensive pharmaceutical enterprise integrating r&d, production and sales, c&o has a complete terminal sales network and sales team with strong terminal sales capability and rich terminal sales experience. as the market space for dermatological drugs is huge, the acquisition of lulite® luliconazole cream distribution rights enriches chang ao’s product line and further consolidates its dominant position in the field of pharmaceutical product terminal sales.

xu yan, general manager of c&o, fukui mahito, vice general manager, wang kai, general manager of liancheng medicine , along with lu yifeng, president of changjiang runfa health, executive president of hailing pharm, li yiqing, vice president of changjiang runfa health, and liu hong, vice general manager of hailing pharm attended this signing ceremony.